A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : IVIVE / in vivo extrapolation

[Related PubMed/MEDLINE]
Total Number of Papers: 66
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   IVIVE  (>> Co-occurring Abbreviation)
Long Form:   in vivo extrapolation
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
1  2022 An in vitro approach to determine the human relevance of anti-spermatogenic effects of 4-methylmorpholine 4-oxide, monohydrate (NMMO) in rat reproductive toxicity studies. MOA, NAM, NMMO, OEDs
2  2022 Application of an Accessible Interface for Pharmacokinetic Modeling and In Vitro to In Vivo Extrapolation. PBPK
3  2022 Characterisation of intravenous pharmacokinetics in Gottingen minipig and clearance prediction using established invitro to invivo extrapolation methodologies. PK
4  2022 Considerations for Improving Metabolism Predictions for In Vitro to In Vivo Extrapolation. HT, NAM
5  2022 Developing an In Vitro to In Vivo Extrapolation (IVIVE) Model to Predict Human Milk-to-Plasma Drug Concentration Ratios. BCRP, Fni,7.0, fup, GMFE, M/P, PSA
6  2022 Evaluation of Inhalation Exposures and Potential Health Impacts of Ingredient Mixtures Using in vitro to in vivo Extrapolation. EADs, EC, HTS, PBPK
7  2022 Evidence of the need for modified well-stirred model in vitro to in vivo extrapolation. fu, MRT, MWSM, Vss
8  2022 Exploration and application of a liver-on-a-chip device in combination with modelling and simulation for quantitative drug metabolism studies. AO, fm, MPS, UGT
9  2022 Impact of High-Throughput Model Parameterization and Data Uncertainty on Thyroid-Based Toxicological Estimates for Pesticide Chemicals. EADs, HTS, NAMs, PODs
10  2022 In vitro to in vivo extrapolation to support the development of the next generation risk assessment (NGRA) strategy for nanomaterials. AOP, NGRA
11  2022 IVIVE: Facilitating the Use of In Vitro Toxicity Data in Risk Assessment and Decision Making. EU, NAMs
12  2022 Predicting transporter mediated drug-drug interactions via static and dynamic physiologically based pharmacokinetic modeling: A comprehensive insight on where we are now and the way forward. PBPK, tDDI
13  2022 Quantification of accurate composition and total abundance of homologous proteins by conserved-plus-surrogate peptide (CPSP) approach: Quantification of UDP glucuronosyltransferases in human tissues. CPSP, fm, HIM, HKM, HLM, HLS9, PBPK, UGTs
14  2022 Quantitative in vitro to in vivo extrapolation for developmental toxicity potency of valproic acid analogues. devTOXqP, dTP, EADs, LELs, PBPK, PK, VPA
15  2022 Quantitative in vitro to in vivo extrapolation of genotoxicity data provides protective estimates of in vivo dose. PODs
16  2022 The next frontier in ADME science: Predicting transporter-based drug disposition, tissue concentrations and drug-drug interactions in humans. CL, REF, TC
17  2021 Arsenic toxicokinetic modeling and risk analysis: Progress, needs and applications. ---
18  2021 Exploring in vitro to in vivo extrapolation for exposure and health impacts of e-cigarette flavor mixtures. EC
19  2021 In Defense of Current Concepts and Applications of Clearance in Drug Development and Therapeutics. PBPK
20  2021 Liver-Based Probabilistic Risk Assessment of Exposure to Organophosphate Esters via Dust Ingestion Using a Physiologically Based Toxicokinetic (PBTK) Model. EDIs, MOE, OPEs, PBTK, RfDs
21  2021 Predictive In Vitro-In Vivo Extrapolation for Time Dependent Inhibition of CYP1A2, CYP2C8, CYP2C9, CYP2C19, and CYP2D6 Using Pooled Human Hepatocytes, Human Liver Microsomes, and a Simple Mechanistic Static Model. CYP450, hHEP, HLM, TDI
22  2021 Successful and Unsuccessful Prediction of Human Hepatic Clearance for Lead Optimization. ---
23  2021 Ultrasensitive Quantification of Drug-metabolizing Enzymes and Transporters in Small Sample Volume by Microflow LC-MS/MS. AADAC, DMETs, DPYD, EPXs, GSTs, PBPK, PONs
24  2020 Albumin-Mediated Uptake Improves Human Clearance Prediction for Hepatic Uptake Transporter Substrates Aiding a Mechanistic In Vitro-In Vivo Extrapolation (IVIVE) Strategy in Discovery Research. CL, CL, ESF, PSu,inf
25  2020 An integrated chemical environment with tools for chemical safety testing. ICE
26  2020 Application of the Extended Clearance Classification System (ECCS) in Drug Discovery and Development: Selection of Appropriate In Vitro Tools and Clearance Prediction. ECCS
27  2020 Comparison of In Vitro to In Vivo Extrapolation Approaches for Predicting Transporter-Mediated Hepatic Uptake Clearance Using Suspended Rat Hepatocytes. BSA, CL, CL
28  2020 In Vitro to In Vivo Extrapolation of Metabolic Clearance for UGT Substrates Using Short-Term Suspension and Long-Term Co-cultured Human Hepatocytes. AFE, UGT
29  2020 In vitro-in silico-based probabilistic risk assessment of combined exposure to bisphenol A and its analogues by integrating ToxCast high-throughput in vitro assays with in vitro to in vivo extrapolation (IVIVE) via physiologically based pharmacokinetic (PBPK) modeling. BPA, BPs, ER, HEDs, PBPK
30  2020 Predicting the effect of tea polyphenols on ticagrelor by incorporating transporter-enzyme interplay mechanism. DDI, EGC, EGCG
31  2020 Prediction of Transporter-Mediated Rosuvastatin Hepatic Uptake Clearance and Drug Interaction in Humans Using Proteomics-Informed REF Approach. CL, CL, CL, PET, REF, RSV, TECs
32  2020 Scaling Factors for Clearance in Adult Liver Cirrhosis. MPPGL
33  2019 Comparative analysis of Rapid Equilibrium Dialysis (RED) and solid phase micro-extraction (SPME) methods for In Vitro-In Vivo extrapolation of environmental chemicals. fuB, RED, SPME
34  2019 Development and Application of a Life-Stage Physiologically Based Pharmacokinetic (PBPK) Model to the Assessment of Internal Dose of Pyrethroids in Humans. CES, CPM, DLM, PBPK
35  2019 Evaluation of the bioaccumulation potential of selected alternative brominated flame retardants in marine fish using in vitro metabolic transformation rates. BCF, BCFTOT, BFRs, HBCDs, PBDEs, PBEB
36  2019 In Vitro-In Vivo Inaccuracy: The CYP3A4 Anomaly. ---
37  2019 Integrating in vitro testing and physiologically-based pharmacokinetic (PBPK) modelling for chemical liver toxicity assessment-A case study of troglitazone. NGRA, PBPK, POD, TGZ
38  2019 Interindividual and Regional Variability in Drug Transporter Abundance at the Human Blood-Brain Barrier Measured by Quantitative Targeted Proteomics. BA, BBB, BMECs, GLUT, OAT, OCT, P-gp
39  2019 InVitro-InVivo Extrapolation and Hepatic Clearance-Dependent Underprediction. ---
40  2019 Semi-solid prodrug nanoparticles for long-acting delivery of water-soluble antiretroviral drugs within combination HIV therapies. ARV, HIV, LA, NRTI, SSPNs
41  2018 An examination of protein binding and protein-facilitated uptake relating to in vitro-in vivo extrapolation. ---
42  2018 Bridging the Data Gap From in vitro Toxicity Testing to Chemical Safety Assessment Through Computational Modeling. AOP, PBTK, POD, TD, TK
43  2018 Physiologically Based Pharmacokinetic and Pharmacodynamic Analysis Enabled by Microfluidically Linked Organs-on-Chips. Organ Chip, PBPK, PD, PK
44  2018 Statistical relationship between metabolic decomposition and chemical uptake predicts bioconcentration factor data for diverse chemical exposures. BCF, PSO, rTK
45  2018 Targeted LC-MS/MS Proteomics-Based Strategy To Characterize in Vitro Models Used in Drug Metabolism and Transport Studies. ER
46  2018 Transcriptional Responses Reveal Similarities Between Preclinical Rat Liver Testing Systems. PRank, TG-GATEs, TGx
47  2017 Determination of Human Hepatic CYP2C8 and CYP1A2 Age-Dependent Expression to Support Human Health Risk Assessment for Early Ages. ---
48  2017 Establishment and assessment of a novel in vitro bio-PK/PD system in predicting the in vivo pharmacokinetics and pharmacodynamics of cyclophosphamide. CP, FAB, PK/PD, RLMs
49  2017 In vitro to in vivo extrapolation for drug-induced liver injury using a pair ranking method. AUC, PRank, ROC
50  2017 In vitro to in vivo extrapolation for high throughput prioritization and decision making. ---
51  2017 Physiological fidelity or model parsimony? The relative performance of reverse-toxicokinetic modeling approaches. PBTK
52  2016 Addressing Early Life Sensitivity Using Physiologically Based Pharmacokinetic Modeling and In Vitro to In Vivo Extrapolation. PBPK
53  2016 In vitro to in vivo extrapolation of biotransformation rates for assessing bioaccumulation of hydrophobic organic chemicals in mammals. BMFs
54  2016 In vivo and In vitro neurochemical-based assessments of wastewater effluents from the Maumee River area of concern. BE, BPA, GS, hu, MAO, NMDA, RO, rt, WWTP
55  2016 The impact of variation in scaling factors on the estimation of internal dose metrics: a case study using bromodichloromethane (BDCM). AUC, BDCM, MPPGL, PBPK
56  2015 A case study on quantitative in vitro to in vivo extrapolation for environmental esters: Methyl-, propyl- and butylparaben. MOS
57  2015 Kidney-on-a-Chip Technology for Drug-Induced Nephrotoxicity Screening. DIKI
58  2015 Probe molecule (PrM) approach in adverse outcome pathway (AOP) based high-throughput screening (HTS): in vivo discovery for developing in vitro target methods. AOP, HTS, MTBE, PK, PrM, PrMs, TBA
59  2014 Deciding on success criteria for predictability of pharmacokinetic parameters from in vitro studies: an analysis based on in vivo observations. CL, Vss
60  2014 Improving in vitro to in vivo extrapolation by incorporating toxicokinetic measurements: a case study of lindane-induced neurotoxicity. MEAs, PBPK
61  2014 Optimized approaches for quantification of drug transporters in tissues and cells by MRM proteomics. MRM, P-gp
62  2014 Quantitative transporter proteomics by liquid chromatography with tandem mass spectrometry: addressing methodologic issues of plasma membrane isolation and expression-activity relationship. BCRP, OATP
63  2014 Species extrapolation of life-stage physiologically-based pharmacokinetic (PBPK) models to investigate the developmental toxicology of ethanol using in vitro to in vivo (IVIVE) methods. BECs, EtOH, PBPK
64  2014 Use of in vitro data in developing a physiologically based pharmacokinetic model: Carbaryl as a case study. ChE, PBPK, PBPK/PD, PD, PK
65  2014 Use of in vitro to in vivo extrapolation to predict the optimal strategy for patients switching from efavirenz to maraviroc or nevirapine. ADME
66  2013 Evaluation of simple in vitro to in vivo extrapolation approaches for environmental compounds. ---